Post by icemandios on Nov 8, 2017 15:30:23 GMT
Array BioPharma To Present At The 2017 Stifel Healthcare Conference
BOULDER, Colo., Nov. 8, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andy Robbins, will present at the 2017 Stifel Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event:
Stifel Healthcare Conference
Presenter:
Andy Robbins, Chief Operating Officer
Date:
Wednesday, November 15, 2017
Time:
11:00 a.m. Eastern Time
Webcast:
wsw.com/webcast/stifel10/arry/
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
BOULDER, Colo., Nov. 8, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andy Robbins, will present at the 2017 Stifel Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event:
Stifel Healthcare Conference
Presenter:
Andy Robbins, Chief Operating Officer
Date:
Wednesday, November 15, 2017
Time:
11:00 a.m. Eastern Time
Webcast:
wsw.com/webcast/stifel10/arry/
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
